Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C (HCV) is a significant global health concern.
• HCV genotype 4 is often challenging to treat with existing antiviral therapies.
• Limited data exists on the efficacy of peginterferon and ribavirin for HCV genotype 4.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a fixed-dose regimen of peginterferon alfa 2a plus ribavirin.
• To assess treatment outcomes in treatment-naive patients with chronic hepatitis C genotype 4.
• To determine early and sustained virological responses to this combination therapy.

Main Methods:

• A prospective, open-label study involving 30 treatment-naive patients with HCV genotype 4.
• Patients received weekly subcutaneous peginterferon alfa 2a (180 mcg) and daily oral ribavirin (1200 mg if body weight > 75 kg) for 48 weeks.
• Follow-up occurred for 24 weeks post-treatment, with virological responses defined by HCV RNA absence at 12 and 72 weeks.

Main Results:

• Early virological response (EVR) was achieved in 83.3% of patients.
• Sustained virological response (SVR) was observed in 63.3% of patients.
• High EVR rates (96.6%) were noted in patients with minimal or absent fibrosis.

Conclusions:

• Peginterferon alfa 2a combined with ribavirin demonstrates effectiveness in treating HCV genotype 4.
• Treatment response rates fall between those seen for genotype 1 and genotypes 2 or 3.
• The fixed-dose regimen is a tolerable and effective option for managing HCV genotype 4.